

PCP

One Step Phencyclidine Test Strip

Package Insert

A rapid, one step test for the qualitative detection of Phencyclidine in human urine.

For healthcare professionals including professionals at point of care sites.

For in vitro diagnostic use only.

INTENDED USE

The PCP One Step Phencyclidine Test Strip is a lateral flow chromatographic immunoassay for the detection of Phencyclidine in urine at a cut-off concentration of 25 ng/mL.

This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

SUMMARY

Phencyclidine, also known as PCP or Angel Dust, is a hallucinogen that was first marketed as a surgical anesthetic in the 1950's. It was removed from the market because patients receiving it became delirious and experienced hallucinations.

Phencyclidine is used in powder, capsule, and tablet form. The powder is either snorted or smoked after mixing it with marijuana or vegetable matter. Phencyclidine is most commonly administered by inhalation but can be used intravenously, intranasally, and orally. After low doses, the user thinks and acts swiftly and experiences mood swings from euphoria to depression. Self-injurious behavior is one of the devastating effects of Phencyclidine.

PCP can be found in urine within 4 to 6 hours after use and will remain in urine for 7 to 14 days, depending on factors such as metabolic rate, user's age, weight, activity, and diet.¹ Phencyclidine is excreted in the urine as unchanged drug (4% to 19%) and conjugated metabolites (25% to 30%).¹

PRINCIPLE

The PCP One Step Phencyclidine Test Strip is an immunoassay based on the principle of competitive binding. Drugs that may be present in the urine specimen compete against the drug conjugate for binding sites on the antibody.

During testing, a urine specimen migrates upward by capillary action. Phencyclidine, if present in the urine specimen below 25 ng/mL, will not saturate the binding sites of the antibody in the test strip. The Phencyclidine conjugate will be captured by antibody and a visible colored line will show up in the test line region. The colored line will not form in the test line region if the Phencyclidine level exceeds 25 ng/mL because it will saturate all the binding sites of anti-Phencyclidine antibodies.

A drug-positive urine specimen will not generate a colored line in the test line region (T) because of drug competition, while a drug-negative urine specimen will generate a line in the test line region because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control line region, indicating that proper volume of specimen has been added and membrane

wicking has occurred.

REAGENTS

The test strip contains mouse monoclonal anti-Phencyclidine antibody-coupled particles and Phencyclidine-protein conjugate. A goat antibody is employed in the control line system.

PRECAUTIONS

- For healthcare professionals including professionals at point of care sites.
- For in vitro diagnostic use only. Do not use after the expiration date.
- The test strip should remain in the sealed pouch until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
- The used test strip should be discarded according to federal, state and local regulations.

STORAGE AND STABILITY

Store as packaged in the sealed pouch at 2-30°C. The test strip is stable through the expiration date printed on the sealed pouch. The test strips must remain in the sealed pouch until use. **DO NOT FREEZE.** Do not use beyond the expiration date.

SPECIMEN COLLECTION AND PREPARATION

Urine Assay

The urine specimen must be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible particles should be centrifuged, filtered, or allowed to settle to obtain a clear specimen for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed before testing.

MATERIALS

Materials Provided

- Test strips
- Package insert

Materials Required But Not Provided

- Specimen collection container
- Timer
- External Controls

DIRECTIONS FOR USE

Allow the test strip, urine specimen, and/or controls to reach room temperature (15-30°C) prior to testing.

1. Bring the pouch to room temperature before opening it. Remove the test strip from the sealed pouch and use it as soon as possible.
2. With arrows pointing toward the urine specimen, immerse the test strip vertically in the urine specimen for at least 10-15 seconds. Do not pass the maximum line (MAX) on the test strip when immersing the strip. See the illustration below.
3. Place the test strip on a non-absorbent flat surface, start the timer and wait for the red line(s) to appear. The result should be read at 5 minutes. Do not interpret

the result after 10 minutes.

INTERPRETATION OF RESULTS

(Please refer to the illustration below)


NEGATIVE:* **Two lines appear.** One red line should be in the control region (C), and another apparent red or pink line should be in the test region (T). This negative result indicates that the Phencyclidine concentration is below the detectable level (25 ng/mL).

***NOTE:** The shade of red in the test line region (T) will vary, but it should be considered negative whenever there is even a faint pink line.

POSITIVE: **One red line appears in the control region (C). No line appears in the test region (T).** This positive result indicates that the Phencyclidine concentration exceeds the detectable level (25 ng/mL).

INVALID: **Control line fails to appear.** Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test strip. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

Test Results



QUALITY CONTROL

A procedural control is included in the test. A red line appearing in the control region (C) is considered an internal positive procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit; however it is recommended that positive and negative controls be tested as good laboratory testing practice to confirm the test procedure and to verify proper test performance.

LIMITATIONS

1. The PCP One Step Phencyclidine Test Strip provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) are the preferred confirmatory methods.^{2,3}
2. It is possible that technical or procedural errors, as well as other interfering substances in the urine specimen may cause erroneous results.
3. Adulterants, such as bleach and/or alum, in urine specimens may produce

erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.

- A Positive Result indicates presence of the drug or its metabolites but does not indicate level or intoxication, administration route or concentration in urine.
- A Negative Result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cutoff level of the test.
- Test does not distinguish between drugs of abuse and certain medications.

PERFORMANCE CHARACTERISTICS

Accuracy

A side-by-side comparison was conducted using the PCP One Step Phencyclidine Test Strip and a leading commercially available PCP rapid test. Testing was performed on 212 clinical. Ten percent of the specimens employed were either at -25% or +25% level of the cut-off concentration of 25 ng/mL Phencyclidine. Presumptive positive results were confirmed by GC/MS. The following results were tabulated:

| Method | Other PCP Rapid Test | | Total Results |
|---|----------------------|----------|---------------|
| PCP One Step Test Strip | Results | Positive | Negative |
| | Positive | 56 | 0 |
| | Negative | 1 | 155 |
| Total Results | | 57 | 155 |
| % Agreement with this commercial kit | | 98% | 100% |

When compared at 25 ng/mL cut-off with GC/MS, the following results were tabulated:

| Method | GC/MS | | Total Results |
|--|----------|----------|---------------|
| PCP One Step Test Strip | Results | Positive | Negative |
| | Positive | 50 | 5 |
| | Negative | 0 | 157 |
| Total Results | | 50 | 162 |
| % Agreement with GC/MS Analysis | | 100% | 97% |

Eighty (80) of these samples were also run using the PCP One Step Phencyclidine Test Strip by an untrained operator at a different site. Based on GC/MS data, the operator obtained a statistically similar Positive Agreement, Negative Agreement and Overall Agreement rate as the laboratory personnel.

Analytical Sensitivity

A drug-free urine pool was spiked with Phencyclidine at the following concentrations: 0 ng/mL, 12.5 ng/mL, 18.75 ng/mL, 25 ng/mL, 31.25 ng/mL and 37.5 ng/mL. The result demonstrates >99% accuracy at 50% above and 50% below the cut-off concentration. The data are summarized below:

| PCP Concentration (ng/mL) | Percent of Cutoff | n | Visual Result | |
|---------------------------|-------------------|----|---------------|----------|
| | | | Negative | Positive |
| 0 | 0% | 30 | 30 | 0 |
| 12.5 | -50% | 30 | 30 | 0 |
| 18.75 | -25% | 30 | 19 | 11 |
| 25 | Cutoff | 30 | 16 | 14 |
| 31.25 | +25% | 30 | 6 | 24 |
| 37.5 | +50% | 30 | 0 | 30 |

Analytical Specificity

The following table lists the compound that is positively detected in urine by the PCP One Step Phencyclidine Test Strip at 5 minutes.

| Compound | Concentration (ng/mL) |
|------------------------|-----------------------|
| 4-Hydroxyphencyclidine | 12,500 |
| Phencyclidine | 25 |

Precision

A study was conducted at 3 physician's offices by untrained operators using 3 different lots of product to demonstrate the within run, between run and between operator precision. An identical panel of coded specimens containing no Phencyclidine, 25% Phencyclidine above and below the cut-off and 50% Phencyclidine above and below the 25 ng/mL cut-off was provided to each site. The following results were tabulated:

| Phencyclidine conc. (ng/mL) | n per site | Site A | | Site B | | Site C | |
|-----------------------------|------------|--------|----|--------|----|--------|----|
| | | - | + | - | + | - | + |
| 0 | 15 | 15 | 0 | 15 | 0 | 15 | 0 |
| 12.5 | 15 | 15 | 0 | 14 | 1 | 14 | 1 |
| 18.75 | 15 | 11 | 4 | 13 | 2 | 10 | 5 |
| 31.25 | 15 | 8 | 7 | 5 | 10 | 1 | 14 |
| 37.5 | 15 | 4 | 11 | 0 | 15 | 0 | 15 |

Effect of Urinary Specific Gravity

Fifteen (15) urine samples with specific gravity ranges from 1.001 to 1.032 were spiked with 12.5 ng/mL and 37.5 ng/mL of Phencyclidine respectively. The PCP One Step Phencyclidine Test Strip was tested in duplicate using the fifteen neat and spiked urine samples. The results demonstrate that varying ranges of urinary specific gravity does not affect the test results.

Effect of the Urinary pH

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with Phencyclidine to 12.5 ng/mL and 37.5ng/mL. The spiked, pH-adjusted urine was tested with the PCP One Step Phencyclidine Test Strip in duplicate and interpreted according to the package insert. The results demonstrate that varying ranges of pH does not interfere with the performance of the test.

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free urine or Phencyclidine positive urine. The following compounds show no cross-reactivity when tested with the PCP One Step Phencyclidine Test Strip at a concentration of 100 µg/mL.

Non Cross-Reacting Compounds

| | | |
|----------------------|------------------------|---------------------------|
| Acetaminophen | β-Estradiol | Oxymetazoline |
| Acetophenetidin | Estrone-3-sulfate | Papaverine |
| N-Acetylprocainamide | Ethyl-p-aminobenzoate | Penicillin-G |
| Acetylsalicylic acid | Fenoprofen | Pentazocine hydrochloride |
| Aminopyrine | Furosemide | Pentobarbital |
| Amitriptyline | Gentisic acid | Perphenazine |
| Amobarbital | Hemoglobin | Phenelzine |
| Amoxicillin | Hydralazine | Phenobarbital |
| Ampicillin | Hydrochlorothiazide | Phentermine |
| Ascorbic acid | Hydrocodone | L-Phenylephrine |
| D,L-Amphetamine | Hydrocortisone | β-Phenylethylamine |
| Apomorphine | O-Hydroxyhippuric acid | Phenylpropanolamine |
| Aspartame | p-Hydroxy- | Prednisolone |
| Atropine | methamphetamine | Prednisone |
| Benzilic acid | 3-Hydroxytyramine | Procaine |
| Benzoic acid | Ibuprofen | Promazine |
| Benzoyllecgonine | Imipramine | Promethazine |
| Benzphetamine | Iproniazid | D,L-Propranolol |
| Bilirubin | (±) - Isoproterenol | D-Propoxyphene |

| | | |
|------------------------|-------------------------|---|
| Brompheniramine | Isoxsuprine | D-Pseudoephedrine |
| Caffeine | Ketamine | Quinidine |
| Cannabidiol | Ketoprofen | Quinine |
| Cannabinol | Labetalol | Ranitidine |
| Chloralhydrate | Loperamide | Salicylic acid |
| Chloramphenicol | Maprotiline | Secobarbital |
| Chlordiazepoxide | Meperidine | Serotonin (5-Hydroxytyramine) |
| Chlorothiazide | Meprobamate | Sulfamethazine |
| (±) Chlorpheniramine | Methadone | Sulindac |
| Chlorpromazine | Methoxyphenamine | Temazepam |
| Chlorquine | (+) 3,4-Methylenedioxy- | Tetracycline |
| Cholesterol | amphetamine | Tetrahydrocortisone, 3 acetate |
| Clomipramine | (+) 3,4-Methylenedioxy- | Tetrahydrocortisone 3 (β-D glucuronide) |
| Clonidine | methamphetamine | Tetrazepam |
| Cocaine hydrochloride | Morphine-3-β-D | Thiamine |
| Codeine | glucuronide | Thioridazine |
| Cortisone | Morphine Sulfate | D, L-Tyrosine |
| (-) Cotinine | Nalidixic acid | Tolbutamide |
| Creatinine | Naloxone | Triamterene |
| Deoxycorticosterone | Naltrexone | Trifluoperazine |
| Dextromethorphan | Naproxen | Trimethoprim |
| Diazepam | Niacinamide | Trimipramine |
| Diclofenac | Nifedipine | Tryptamine |
| Diflunisal | Norcodein | D, L-Tryptophan |
| Digoxin | Norethindrone | Tyramine |
| Diphenhydramine | D-Norpropoxyphene | Uric acid |
| Doxylamine | Noscapine | Verapamil |
| Ecgonine hydrochloride | D,L-Octopamine | Zomepirac |
| Ecgonine methylester | Oxalic acid | |
| (-) Y Ephedrine | Oxazepam | |
| Erythromycin | Oxolinic acid | |
| | Oxycodone | |

BIBLIOGRAPHY

- Robert DeCresce. *Drug Testing in the workplace*, 114
- Baselt RC. *Disposition of Toxic Drugs and Chemicals in Man*. 2nd Ed. Biomedical Publ., Davis, CA. 1982; 488
- Hawks RL, CN Chiang. *Urine Testing for Drugs of Abuse*. National Institute for Drug Abuse (NIDA), Research Monograph 73, 1986

Printed in China

DN: R015425-02
Eff. Date: March 25, 2002